dihydrohonokiol-B

Dihydrohonokiol-B (DHH-B) is a small molecule derived from magnolia bark and is a partially reduced derivative of honokiol. It acts as a potent anxiolytic agent in preclinical models without causing the motor dysfunction, sedation, amnesia, or physical dependence typically associated with benzodiazepines[1][4][7]. Its primary mechanism involves modulation of the GABA(A) receptor-gated chloride channel complex in the brain. Evidence suggests that DHH-B may act as an agonist at benzodiazepine receptors and also stimulate GABA-C receptors[1][2][6]. The anxiolytic effect of DHH-B can be blocked by flumazenil (a benzodiazepine receptor antagonist), but not by bicuculline (a GABA-A antagonist), indicating its action through the benzodiazepine site on GABA-A receptors[2]. Additionally, it has demonstrated neuroprotective effects against amyloid beta-induced toxicity in neuronal models via activity on GABA-C receptors[6]. DHH-B is marketed primarily as a dietary supplement for anxiety relief and sleep enhancement.

Brand names

DHH-B

Other names

3'-(2-propenyl)-5-propyl-(1,1'-biphenyl)-2,4'-diol3'-allyl-5-propyl-[1,1'-biphenyl]-2,4'-dioldihydrohonokiol